Journal
CLINICAL IMMUNOLOGY
Volume 155, Issue 1, Pages 79-90Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.clim.2014.09.002
Keywords
Systemic lupus erythematosus (SLE); Biomarkers; Pharmacoepigenetics; HDAC inhibitors; DNA methylation; microRNA
Categories
Funding
- National Natural Science Foundation of China [81220108017, 81373205, 81270024]
- Hunan Provincial Natural Science Foundation of China [14JJ1009]
- programs of Science-Technology Commission of Hunan Province [2013FJ4202, 2011FJ2007, 2012WK3046]
- National Key Clinical Speciality Construction Project of the National Health and Family Planning Commission of the People's Republic of China
Ask authors/readers for more resources
The current treatments of systemic lupus erythematosus (SLE) have been based on the use of immunosuppressive drugs which are linked to serious side effects. The more effective therapeutic approaches with minimal or no side effects for SLE patients are hard to develop, mainly due to the complexity of the disease. The discovery of pharmacoepigenetics provides a new way to solve this problem. Epigenetic modifications can influence drug efficacy by altering gene expression via changing chromatin structure. Although still in early development, epigenetic studies in SLE are expected to reveal novel therapeutic targets and disease biomarkers in autoimmunity. For example, miRNAs, which have been identified to govern many genes including drug targets, are altered in disease development and after drug administration. This review aims to present an overview of current epigenetic mechanisms involved in the pathogenesis of SLE, and discuss their potential roles in clinical and pharmacological applications. (C) 2014 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available